Correlation Between Huang Hsiang and Medigen Biotechnology

Can any of the company-specific risk be diversified away by investing in both Huang Hsiang and Medigen Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Huang Hsiang and Medigen Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Huang Hsiang Construction and Medigen Biotechnology, you can compare the effects of market volatilities on Huang Hsiang and Medigen Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Huang Hsiang with a short position of Medigen Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Huang Hsiang and Medigen Biotechnology.

Diversification Opportunities for Huang Hsiang and Medigen Biotechnology

-0.54

Correlation Coefficient

Huang Hsiang  Medigen Biotechnology

Excellent diversification

The 3 months correlation between Huang and Medigen is -0.54. Overlapping area represents the amount of risk that can be diversified away by holding Huang Hsiang Construction and Medigen Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Medigen Biotechnology and Huang Hsiang is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Huang Hsiang Construction are associated (or correlated) with Medigen Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Medigen Biotechnology has no effect on the direction of Huang Hsiang i.e., Huang Hsiang and Medigen Biotechnology go up and down completely randomly.

Pair Corralation between Huang Hsiang and Medigen Biotechnology

Assuming the 90 days trading horizon Huang Hsiang Construction is expected to under-perform the Medigen Biotechnology. In addition to that, Huang Hsiang is 1.65 times more volatile than Medigen Biotechnology. It trades about -0.39 of its total potential returns per unit of risk. Medigen Biotechnology is currently generating about -0.27 per unit of volatility. If you would invest  3,495  in Medigen Biotechnology on September 24, 2024 and sell it today you would lose (345.00) from holding Medigen Biotechnology or give up 9.87% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Huang Hsiang Construction  vs.  Medigen Biotechnology

Huang Hsiang Construction

Risk-Adjusted Performance

4 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Huang Hsiang Construction are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Huang Hsiang may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Medigen Biotechnology

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Medigen Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Pair Trading with Huang Hsiang and Medigen Biotechnology

The main advantage of trading using opposite Huang Hsiang and Medigen Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Huang Hsiang position performs unexpectedly, Medigen Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medigen Biotechnology will offset losses from the drop in Medigen Biotechnology's long position.

The idea behind Huang Hsiang Construction and Medigen Biotechnology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.